Tinlorafenib (PF-07284890) (compound 10) is an orally active BRAF kinase inhibitor, with IC 50 s of 4.25 and 2.7 nM for BRAF respectively. Tinlorafenib demonstrates CNS penetration and can be used in the research of BRAF-associated malignant and benign tumors of the CNS as well as extracranial malignancies.
性状
Solid
IC50 & Target[1][2]
BRaf 4.25 nM (IC50) BRaf 2.7 nM (IC50
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years;4°C 2 years
ClinicalTrial
参考文献
[1]. Barbour, et al. Quinazolin-4-one derivatives useful for the treatment of braf-associated diseases and disorders. WO2020261156A1.
溶解度数据
In Vitro: DMSO : 125 mg/mL (273.59 mM; Need ultrasonic)配制储备液